Antiretroviral Therapy and HIV/Hepatitis B Virus Coinfection

Clinical Infectious Diseases

Volumn 38, Issue SUPPL. 2, 2004, Pages

  Benhamou, Yves ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ANTIRETROVIRUS AGENT; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; PLACEBO; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; ADENINE; ANTIVIRUS AGENT; DRUG DERIVATIVE; ORGANOPHOSPHORUS COMPOUND; PHOSPHONIC ACID DERIVATIVE;

CAUSE OF DEATH; CLINICAL TRIAL; COMORBIDITY; CONFERENCE PAPER; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; HEPATITIS B; HEPATITIS B VIRUS; HIGH RISK PATIENT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER CIRRHOSIS; LIVER DISEASE; LIVER TOXICITY; MONOTHERAPY; OPEN STUDY; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; VIRUS STRAIN; ARTICLE; ISOLATION AND PURIFICATION;

ADENINE; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTIVIRAL AGENTS; HEPATITIS B; HEPATITIS B VIRUS; HIV; HIV INFECTIONS; HUMANS; LAMIVUDINE; ORGANOPHOSPHORUS COMPOUNDS; PHOSPHONIC ACIDS;

EID: 1542297626     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/381451     Document Type: Conference Paper

References (39)

1. Maddrey WC. Hepatitis B: an important public health issue. Clin Lab 2001; 47:51-5.
2. Rustgi VK, Hoofnagle JH, Gerin JL, al. Hepatitis B infection in the acquired immunodeficiency syndrome. Ann Intern Med 1984; 101:795-7.
3. Bodsworth NJ, Cooper DA, Donovan B. The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B virus carrier state. J Infect Dis 1991; 163:1138-40.
4. Gilson RJ, Hawkins AE, Beecham MR, et al. Interactions between HIV and hepatitis B virus in homosexual men: effects on the natural history of infection. AIDS 1997; 11:597-606.
5. Taylor PE, Stevens CE, DeCordoba SR, Rubinstein P. Hepatitis B virus and human immunodeficiency virus: Possible interactions. In: Zuckerman AJ, ed. Viral hepatitis and liver disease. New York: Alan R Liss, 1988; 198-200.
6. Perrillo RP, Regenstein FG, Roodman ST. Chronic hepatitis B in asymptomatic homosexual men with antibody to the human immunodeficiency virus. Ann Intern Med 1986; 105:382-3.
7. Rector WG Jr, Govindarajan S, Horsburgh CR Jr, Penley KA, Cohn DL, Judson FN. Hepatic inflammation, hepatitis B replication, and cellular immune function in homosexual males with chronic hepatitis B and antibody to human immunodeficiency virus. Am J Gastroenterol 1988; 83:262-6.
8. Colin JF, Cazals-Hatem D, Loriot MA, et al. Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology 1999; 29:1306-10.
9. Puoti M, Spinetti A, Ghezzi A, et al. Mortality for liver disease in patients with HIV infection: a cohort study. J Acquir Immune Defic Syndr 2000; 24:211-7.
10. Thio CL, Seaberg EC, Skolasky R Jr, et al. Multicenter AIDS Cohort Study: HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002; 360:1921-6.
11. Benhamou Y, Katlama C, Lunel F, et al. The effects of lamivudine on replication of hepatitis B virus in HIV-infected men. Ann Intern Med 1996; 125:705-12.
12. Dore GJ, Cooper DA, Barren C, Goh LE, Thakrar B, Atkins M. Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee. J Infect Dis 1999; 180:607-13.
13. CAESAR Coordinating Committee. Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine containing regimens for patients with HIV-1 infection: the CAESAR trial. Lancet 1997; 349:1413-21.
14. Schuurman R, Nijhuis M, van Leeuwen R, et al. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis 1995; 171:1411-9.
15. Bartholomew MM, Jansen RW, Lennox JJ, et al. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 1997; 349:20-2.
16. Ling R, Mutimer D, Ahmed M, et al. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 1996; 24:711-3.
17. Benhamou Y, Bochet M, Thibault V, et al. Long term incidence of hepatitis B virus resistance to lamivudine in HIV-infected patients. Hepatology 1999; 30:1302-6.
18. Thibault V, Benhamou Y, Seguret C, et al. Hepatitis B virus (HBV) mutations associated with resistance to lamivudine in patients co-infected with HBV and human immunodeficiency virus. J Clin Microbiol 1999; 37:3013-6.
19. Pillay D, Cane PA, Ratcliffe D, Atkins M, Cooper D. Evolution of lamivudine-resistant hepatitis B virus and HIV-1 in co-infected individuals: an analysis of the CAESAR study. CAESAR co-ordinating committee. AIDS 2000; 14:1111-6.
20. Perrillo RP. Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology 2001; 120:1009-22.
21. Bruno R, Sacchi P, Malfitano A, Filice G. YMDD-mutant HBV strain as a cause of liver failure in an HIV-infected patient. Gastroenterology 2001; 121:1027-8.
22. Bonacini M, Kurz A, Locarnini S, Ayres A, Gibbs C. Fulminant hepatitis B due to a lamivudine-resistant mutant of HBV in a patient coinfected with HIV. Gastroenterology 2002; 122:244-5.
23. Bessesen M, Ives D, Condreay L, Lawrence S, Sherman KE. Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine. Clin Infect Dis 1999; 28:1032 5.
24. Xiong X, Flores C, Fuller M, et al. In vitro characterization of the anti-human cytomegalovirus activity of PMEA (adefovir). Antiviral Res 1997; 36:131-7.
25. Xiong X, Flores C, Yang H, Toole J, Gibbs C. Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro. Hepatology 1998; 28:1669-73.
26. Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis Be antigen-positive chronic hepatitis B. N Engl J Med 2003; 348:808-16.
27. Hadziyannis SJ, Tassopoulos NC, Heathcote E, et al. Adefovir dipivoxil for the treatment of hepatitis Be antigen-negative chronic hepatitis B. N Engl J Med 2003; 348:800-7.
28. Benhamou Y, Bochet M, Thibault V, et al. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus. Lancet 2001; 358:718-23.
29. Benhamou Y, Bochet M, Thibault V, et al. Safety and efficacy of long-term adefovir dipivoxil (ADV) for lamivudine-resistant (LAM-R) HBV in HIV infected patients. J Hepatol 2002; 36(Supp 1):138.
30. Peters M, Hann HW, Martin P, et al. Adefovir dipivoxil alone and in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004; 126:91-101.
31. Ying C, De Clercq E, Nicholson W, Furman P, Neyts J. Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, L-FMAU, DAPD, penciclovir and lobucavir. J Viral Hepat 2000; 7:161-5.
32. Benhamou Y, Bochet M, Tubiana R, et al. Tenofovir disoproxil fumarate suppresses lamivudine resistant HBV replication in patients co-infected with HIV/HBV. N Engl J Med 2003; 348:177-8.
33. Cooper D, Cheng A, Coakley D, et al. Anti-HBV activity of tenofovir disoproxil fumarate (TDF) in lamivudine (LAM) experienced HIV/HBV co-infected patients [abstract 124]. In: Program and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections (Seattle). Alexandria, VA: Foundation for Retrovirology and Human Health, 2002:124.
34. Nelson M, Portsmouth S, Stebbing J, et al. An open-label study of tenofovir in HIV-1 and hepatitis B virus co-infected individuals. AIDS 2003; 17:F7-10.
35. Ristig MB, Crippin J, Aberg JA, et al. Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-α and lamivudine therapy have failed. J Infect Dis 2002; 186:1844-7.
36. Sulkowski MS, Thomas DL, Mehta SH, Chaisson RE, Moore RD. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology 2002; 35:182-9.
37. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Elevated liver enzymes following initiation of antiretroviral therapy. JAMA 2000; 283: 2526-7.
38. Saves M, Vandentorren S, Daucourt V, et al. Severe hepatic cytolysis: incidence and risk factors in patients treated by antiretroviral combinations. Aquitaine Cohort, France, 1996-1998. Groupe d'Epidemiologie Clinique de Sida en Aquitaine (GECSA). AIDS 1999; 13:F115-21.
39. Nunez M, Lana R, Mendoza JL, Martin-Carbonero L, Soriano V. Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2001; 27:426-31.